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Background:  Based upon results of the ACTIVE-A trial aspirin (ASA) 81mg daily plus clopidogrel (clop) is recommended for atrial fibrillation (AF) 
patients ineligible for vitamin K antagonists (VKA) as stated in the 2010 European guidelines (IIa LOE B). The 2007 American guidelines (I LOE A) 
recommend ASA alone (81-325mg daily). However, recently the AVERROES trial (the oral direct factor Xa antagonist apixaban versus ASA alone in 
5,600 VKA ineligible patients) was presented and is compared with ACTIVE-A.
Methods:  Baseline features, clinical efficacy and bleeding complications per year are given for the treatment groups of both the double-blind 
ACTIVE-A and the AVERROES trials, and for the control groups with aspirin monotherapy (n=13,154).
Results:  Baseline risk was highly comparable in both trials (table).
Conclusion: Apixaban and to a lesser extent aspirin with clopidogrel reduce stroke in comparison to aspirin alone in VKA ineligible AF patients, but 
apixaban seems safer than dual antiplatelet therapy. The results with apixaban look also promising for the results of the upcoming ARISTOTLE study 
which compares VKA with apixaban in VKA eligible patients. 
AVERROES ACTIVE-A
apixaban 
(n=2,809)
ASA 
(n=2,791)
ASA 
(n=3,782)
ASA+clop 
(n=3,772)
CHADS
2
-score 2.1 2.1 2.0 2.0
Age (y) 70 70 71 71
Women (%) 41 42 42 41
Total strokes (%/y) 1.5 3.3 3.3 2.4
Disabling & fatal strokes (%/y) 0.9 2.1 2.1 1.6
Major bleeding (%/y) 1.4 1.2 1.3 2.0
